147 related articles for article (PubMed ID: 24729466)
1. Low-dose irinotecan improves advanced lupus nephritis in mice potentially by changing DNA relaxation and anti-double-stranded DNA binding.
Frese-Schaper M; Keil A; Steiner SK; Gugger M; Körner M; Kocher GJ; Schiffer L; Anders HJ; Huynh-Do U; Schmid RA; Frese S
Arthritis Rheumatol; 2014 Aug; 66(8):2259-69. PubMed ID: 24729466
[TBL] [Abstract][Full Text] [Related]
2. The Topoisomerase I Inhibitor Irinotecan and the Tyrosyl-DNA Phosphodiesterase 1 Inhibitor Furamidine Synergistically Suppress Murine Lupus Nephritis.
Keil A; Frese-Schaper M; Steiner SK; Körner M; Schmid RA; Frese S
Arthritis Rheumatol; 2015 Jul; 67(7):1858-67. PubMed ID: 25779651
[TBL] [Abstract][Full Text] [Related]
3. Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan.
Keil A; Hall SR; Körner M; Herrmann M; Schmid RA; Frese S
Arthritis Res Ther; 2016 Oct; 18(1):243. PubMed ID: 27770825
[TBL] [Abstract][Full Text] [Related]
4. Reversal of established lupus nephritis and prolonged survival of New Zealand black x New Zealand white mice treated with the topoisomerase I inhibitor irinotecan.
Frese-Schaper M; Zbaeren J; Gugger M; Monestier M; Frese S
J Immunol; 2010 Feb; 184(4):2175-82. PubMed ID: 20083657
[TBL] [Abstract][Full Text] [Related]
5. CXCR3 promotes the production of IgG1 autoantibodies but is not essential for the development of lupus nephritis in NZB/NZW mice.
Moser K; Kalies K; Szyska M; Humrich JY; Amann K; Manz RA
Arthritis Rheum; 2012 Apr; 64(4):1237-46. PubMed ID: 22006377
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB x NZW)F1 mouse.
Werwitzke S; Trick D; Kamino K; Matthias T; Kniesch K; Schlegelberger B; Schmidt RE; Witte T
Arthritis Rheum; 2005 Nov; 52(11):3629-38. PubMed ID: 16255055
[TBL] [Abstract][Full Text] [Related]
7. Critical comparative analyses of anti-alpha-actinin and glomerulus-bound antibodies in human and murine lupus nephritis.
Kalaaji M; Sturfelt G; Mjelle JE; Nossent H; Rekvig OP
Arthritis Rheum; 2006 Mar; 54(3):914-26. PubMed ID: 16508974
[TBL] [Abstract][Full Text] [Related]
8. Reduced fragmentation of apoptotic chromatin is associated with nephritis in lupus-prone (NZB x NZW)F(1) mice.
Zykova SN; Seredkina N; Benjaminsen J; Rekvig OP
Arthritis Rheum; 2008 Mar; 58(3):813-25. PubMed ID: 18311834
[TBL] [Abstract][Full Text] [Related]
9. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
Werwitzke S; Trick D; Sondermann P; Kamino K; Schlegelberger B; Kniesch K; Tiede A; Jacob U; Schmidt RE; Witte T
Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
[TBL] [Abstract][Full Text] [Related]
10. Effective therapy for nephritis in (NZB x NZW)F1 mice with triptolide and tripdiolide, the principal active components of the Chinese herbal remedy Tripterygium wilfordii Hook F.
Tao X; Fan F; Hoffmann V; Gao CY; Longo NS; Zerfas P; Lipsky PE
Arthritis Rheum; 2008 Jun; 58(6):1774-83. PubMed ID: 18512813
[TBL] [Abstract][Full Text] [Related]
11. Effect of an exogenous trigger on the pathogenesis of lupus in (NZB x NZW)F1 mice.
Yoshida H; Satoh M; Behney KM; Lee CG; Richards HB; Shaheen VM; Yang JQ; Singh RR; Reeves WH
Arthritis Rheum; 2002 Aug; 46(8):2235-44. PubMed ID: 12209530
[TBL] [Abstract][Full Text] [Related]
12. Pim-1 as a Therapeutic Target in Lupus Nephritis.
Fu R; Xia Y; Li M; Mao R; Guo C; Zhou M; Tan H; Liu M; Wang S; Yang N; Zhao J
Arthritis Rheumatol; 2019 Aug; 71(8):1308-1318. PubMed ID: 30791224
[TBL] [Abstract][Full Text] [Related]
13. Cross-reactivity of antiidiotypic antibodies with DNA in systemic lupus erythematosus.
Eivazova ER; McDonnell JM; Sutton BJ; Staines NA
Arthritis Rheum; 2000 Feb; 43(2):429-39. PubMed ID: 10693885
[TBL] [Abstract][Full Text] [Related]
14. Function of the Th17/interleukin-17A immune response in murine lupus nephritis.
Schmidt T; Paust HJ; Krebs CF; Turner JE; Kaffke A; Bennstein SB; Koyro T; Peters A; Velden J; Hünemörder S; Haag F; Steinmetz OM; Mittrücker HW; Stahl RA; Panzer U
Arthritis Rheumatol; 2015 Feb; 67(2):475-87. PubMed ID: 25385550
[TBL] [Abstract][Full Text] [Related]
15. Delayed lupus onset in (NZB x NZW)F1 mice expressing a human C-reactive protein transgene.
Szalai AJ; Weaver CT; McCrory MA; van Ginkel FW; Reiman RM; Kearney JF; Marion TN; Volanakis JE
Arthritis Rheum; 2003 Jun; 48(6):1602-11. PubMed ID: 12794828
[TBL] [Abstract][Full Text] [Related]
16. Decrease in glomerulonephritis and Th1-associated autoantibody production after progesterone treatment in NZB/NZW mice.
Hughes GC; Martin D; Zhang K; Hudkins KL; Alpers CE; Clark EA; Elkon KB
Arthritis Rheum; 2009 Jun; 60(6):1775-84. PubMed ID: 19479860
[TBL] [Abstract][Full Text] [Related]
17. T cell cytokine imbalance towards production of IFN-gamma and IL-10 in NZB/W F1 lupus-prone mice is associated with autoantibody levels and nephritis.
Enghard P; Langnickel D; Riemekasten G
Scand J Rheumatol; 2006; 35(3):209-16. PubMed ID: 16766368
[TBL] [Abstract][Full Text] [Related]
18. Camptothecin and Topotecan, Inhibitors of Transcription Factor Fli-1 and Topoisomerase, Markedly Ameliorate Lupus Nephritis in (NZB × NZW)F1 Mice and Reduce the Production of Inflammatory Mediators in Human Renal Cells.
Wang X; Oates JC; Helke KL; Gilkeson GS; Zhang XK
Arthritis Rheumatol; 2021 Aug; 73(8):1478-1488. PubMed ID: 33559345
[TBL] [Abstract][Full Text] [Related]
19. Suppression of glomerulonephritis in lupus-prone NZB × NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinase.
Mina-Osorio P; LaStant J; Keirstead N; Whittard T; Ayala J; Stefanova S; Garrido R; Dimaano N; Hilton H; Giron M; Lau KY; Hang J; Postelnek J; Kim Y; Min S; Patel A; Woods J; Ramanujam M; DeMartino J; Narula S; Xu D
Arthritis Rheum; 2013 Sep; 65(9):2380-91. PubMed ID: 23754328
[TBL] [Abstract][Full Text] [Related]
20. Prevention of lupus nephritis development in NZB/NZW mice by selective blockade of CD28.
Laurent L; Le Fur A; Bloas RL; Néel M; Mary C; Moreau A; Poirier N; Vanhove B; Fakhouri F
Eur J Immunol; 2017 Aug; 47(8):1368-1376. PubMed ID: 28631301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
